Predicting Gastric Cancer Response to Chemo With Multimodal AI Model

A Radio-Pathomic Multimodal Machine Learning Model for Predicting Pathological Complete Response to Neoadjuvant Chemotherapy in Advanced Gastric Cancer: A Retrospective Observational Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06451393

Enrollment

500

Registered

2024-06-11

Start date

2013-02-01

Completion date

2026-12-30

Last updated

2024-06-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy Effect, Gastric Cancer

Keywords

Advanced gastric cancer, Neoadjuvant chemotherapy, Multimodal, Pathological complete response

Brief summary

This study aims to develop a multimodal model combining radiomic and pathomic features to predict pathological complete response (pCR) in advanced gastric cancer patients undergoing neoadjuvant chemotherapy (NAC). The researchers intended to collected pre-intervention CT images and pathological slides from patients, extract radiomic and pathomic features, and build a prediction model using machine learning algorithms. The model will be validated using a separate cohort of patients. This research intend to build a radiomic-pathomic model that can outperform models based on either radiomic or pathomic features alone, aiming to improve the prediction of pCR in gastric cancer.

Interventions

DRUGNeoadjuvant chemotherapy with radical tumor resection surgery

All patients were pathologically diagnosed as advanced gastric cancer, all receive neoadjuvant chemotherapy, after the completion of neoadjuvant chemotherapy, all patients receive radical tumor resection surgery (partial gastrectomy or total gastrectomy, as proper).

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

20 Years to 90 Years

Healthy volunteers

Inclusion criteria

* patients with histologically confirmed adenocarcinoma of the stomach or esophagogastric junction who received NAC and radical gastrectomy; * patients who underwent abdominal multidetector computed tomography (CT) inspection, gastroscope, and tumor tissue biopsy before any intervention started; * Lesions that are assessable according to The Response Evaluation Criteria in Solid Tumors Version 1.1

Exclusion criteria

* Patients with indistinguishable tumor lesions on the CT images due to insufficient filling of the stomach during the CT inspection; * patients without indistinguishable tumor cell on the pathological slides due to inadequate sampling; * patients with insufficient data.

Design outcomes

Primary

Measure	Time frame	Description
Pathological Complete Response	Assessed within 30 days after radical resection surgery.	Pathological complete response (pCR) was defined as no viable cells remained in the primary tumor lesions and the dissected lymph nodes.

Countries

China

Contacts

Primary ContactYonghe Chen, MD

chenyhe@mail2.sysu.edu.cn+86 135 6038 6150

Backup ContactJunsheng Peng, MD

pengjsh@mail.sysu.edu.cn+86 13802963578

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026